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Objective To compare the in vitro activity of BMS284756, a desfluoroquinolone, with
four fluoroquinolones against 129 Pseudomonas aeruginosa strains, 97 Stenotrophomonas/
Burkholderia group strains and 43 Acinetobacter spp. strains by three in vitro test methods.
Methods The activity of BMS284756 was determined using the NCCLS reference broth
microdilution method and E test (AB Biodisk, Solna, Sweden). These methods were
compared for test accuracy, and 5-mg disk zone diameters were compared for inter-
pretative accuracy using the susceptible breakpoint of 4 mg/L recommended by the
manufacturer. All strains tested were derived from the 1999–2000 SENTRY Antimicrobial
Surveillance Program organism collection.
Results Comparative quinolone potency against P. aeruginosa was as follows: cipro-
floxacin (MIC50, 0.25 mg/L)> gemifloxacin (MIC50, 0.5 mg/L)> levofloxacin¼ gatiflox-
50, 1 mg/L)>BMS284756 (MIC50, 4 mg/L). The MIC50 value for BMS284756 versus
Stenotrophomonas/Burkholderia group was 2 mg/L. This potency was similar to that of
other quinolones reported previously. The MIC50 results for the Acinetobacter spp. were
ciprofloxacin at >2 mg/L, levofloxacin, gatifloxacin and gemifloxacin at 4 mg/L, and
BMS284756 at >4 mg/L, all intermediate or resistant concentrations. The E test results
compared favorably with the reference dilution test results for P. aeruginosa, Stenotro-
phomonas/Burkholderia group, and Acinetobacter spp., with an overall essential agreement
of 97.0% 2 log2 dilution steps. E test MIC results tended to be slightly lower when
testing Stenotrophomonas/Burkholderia group strains. The disk diffusion method correlated
well for P. aeruginosa (r¼ 0.94), Stenotrophomonas/Burkholderia group (r¼ 0.84) and Aci-
netobacter spp. (r¼ 0.99) strains.
Conclusions BMS284756 was generally less active than other comparison quinolones
when tested against non-fermentative Gram-negative bacilli. Its spectrum remains equiva-
lent only if dosing schedules substantiate a proposed susceptible breakpoint of4 mg/L.
Keywords BMS284756, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Acinetobacter
spp., Burkholderia spp., E test
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I N T R O D U C T I O N
Among the clinically important non-fermenting
Gram-negative bacilli, the most commonly
isolated species are Pseudomonas aeruginosa, Steno-
trophomonas maltophilia/Burkholderia and Acineto-
bacter spp. [1–5]. These opportunistic pathogens
are usually found in the environment, but can
become problematic as nosocomial pathogens in
the generally at-risk patient populations, often in
the intensive care unit (ICU), [3]. Because these
non-fermenters tend to be resistant to many anti-
microbial agents, a search for newer agents to use
for therapy is imperative.
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BMS284756 (formerly T-3811) is a novel des-
fluoroquinolone. It has been shown to be among
the most active quinolones against Gram-positive
bacteria and anaerobic bacterial strains [6,7]. This
study compares the activity of this new desfluor-
oquinolone and other fluorinated quinolones
against the three most commonly isolated groups
of non-fermenters from hospitalized patient infec-
tions. The results obtained from disk diffusion and
E test (AB Biodisk, Solna, Sweden) methods [8]
were also compared to those produced by the
reference broth microdilution method described
by the National Committee for Clinical Laboratory
Standards (NCCLS) [9].
M A T E R I A L S A N D M E T H O D S
Organisms tested
The bacterial strains tested in this study consisted
of Pseudomonas aeruginosa (129 strains), Stenotro-
phomonas/Burkholderia group (97 strains) and Aci-
netobacter spp. (Acinetobacter baumannii complex
and Acinetobacter lwoffii; 43 strains). All organisms
were selected from the SENTRY Antimicrobial
Surveillance Program collection isolated in 1999–
2000 [4]. These organisms were isolated in medical
centers in Europe and the Americas, all processed
at the University of Iowa (R. N. Jones, monitor)
and analyzed elsewhere (North Liberty, IA, USA).
Identification to species level was performed by
routine procedures used at the laboratory of origin
and by the monitor [10–12].
Susceptibility test methods
All organisms were tested by the reference broth
microdilution method and the standardized disk
diffusion test [9,13]. The broth microdilution trays
were produced by TREK Diagnostics, Inc. (Wes-
tlake, OH, USA) and were validated to be equiva-
lent to NCCLS reference tests [9,13,14]. The
BMS284756 5-mg disks were made by BD Micro-
biology Systems (Cockeysville, MD, USA). E tests
(AB Biodisk) were performed as described in the
manufacturer product package insert on Mueller–
Hinton agar plates.
The broth microdilution results were compared
to the E test results. Inter-method essential agree-
ment was defined as the E test result (MIC) being
within 2 log2 dilution of the reference result for
90% of strains. The disk diffusion tests were
compared using the susceptibility breakpoint of
4 mg/L [7] advocated by the manufacturer. Lin-
ear regression statistics and the determination of
potential interpretive errors were used to assess
diagnostic accuracy, applying M23-A2 criteria
[14].
Quality control (QC) was achieved by regular
testing of Pseudomonas aeruginosa ATCC 27853 and
ensuring that all reference test values fell within
the ranges suggested by NCCLS [15] guidelines or
sponsor-generated QC limits (BMS284756), later
confirmed in trials supervised by this laboratory
(Biedenbach et al., unpublished) and accepted by
the NCCLS Subcommittee in June 2001.
R E S U L T S
In the group of non-fermentative Gram-negative
bacilli shown in Table 1, it was found that the
potency of BMS284756 was less than that of other
tested quinolones. However, the BMS284756 spec-
trum of activity as demonstrated by the percentage
susceptibility (4 mg/L) was, in general, similar to
those of the other agents. The selected Acinetobacter
spp. isolates were shown to have the least suscept-
ibility to the quinolones tested, with percentage
rates of only 34.9–39.5%. Of the 129 strains of
Pseudomonas aeruginosa tested, BMS284756 had a
2 to 4-fold higher MIC50 compared to ciprofloxacin
or levofloxacin. Gemifloxacin had a lower MIC50
(0.5 mg/L), yet the percentage of susceptibility
was lower (45.0%), corresponding to its lower
bioavailability. The Stenotrophomonas/Burkholderia
group (97 strains) had equivalent MIC50 results
(2 mg/L) for BMS284756 and ciprofloxacin, but a
smaller proportion of strains were inhibited by
ciprofloxacin (43.3% versus 83.5%; BMS284756 at
2 mg/L was 60.8%).
Table 2 and Figure 1a show the inter-method
comparison results for the BMS284756 E test and
disk diffusion methods using Pseudomonas aerugi-
nosa strains. E test results for 129 organisms
showed a slightly lower value, but 128 of 129
results were within 1 log2 dilution of the refer-
ence broth microdilution MIC (Table 2). Similarly,
the disk diffusion zone diameters around a 5-mg
BMS284756 disk correlated well (r¼ 0.95), and a
possiblebreakpointMICof4 mg/L(correlatezone
of 15 mm) would produce no false-susceptible
(very major) errors and only 0.8% false-resistant
(major) discrepancies.
Also in Table 2 and Figure 1b are statistics com-
paring BMS284756 E test and disk diffusion results
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to those produced by reference NCCLS methods
[9] using 43 strains of Acinetobacter spp. These
highly resistant strains demonstrated a clear bimo-
dal MIC population distribution for BMS284756
(0.12 and 4 mg/L). E test MIC results were all
within 1 log2 dilution, and the correlation coeffi-
cient for the disk diffusion test (r¼ 0.99) was
nearly perfect. Applying the interpretive criteria
for susceptibility listed above, no very major errors
were encountered and 4.7% major errors.
The comparisons of E test and disk diffusion
results to reference test MICs using 97 strains of S.
maltophilia and Burkholderia spp. are listed in
Table 2 and Figure 1c. E test results were clearly
skewed towards a lower MIC value (65.9% 1 log2
dilution). The correlation coefficient (r) for the
disk diffusion test was also decreased to 0.84.
Application of the 4 mg/L and 15 mm suscep-
tible breakpoints produced a modest potential
for only very major and minor types of errors
(5.2% combined). Overall, the E test results
for the so-called ‘non-fermenters’ (269 strains)
had an essential agreement 1 log2 dilution of
nearly 90% and 97.0% 2 log2 dilutions. The use
of a lower, alternative breakpoint MIC for
BMS284756 (susceptible at 2 mg/L and
17 mm) would have combined error rates for
the disk diffusion test of: very major¼ 0.7%,
major¼ 0.0%, and minor errors¼ 8.9%. The selec-
tion of breakpoints of 2 or 4 mg/L [7] with
correlate zone diameter criteria awaits results from
the clinical trials.
Table 1 Activity of BMS284756 and four comparison quinolones tested against 279 strains of Pseudomonas aeruginosa,
Stenotrophomonas/Burkholderia group and Acinetobacter spp
MIC (mg/L)
Organism/antimicrobial agent (no. tested) MIC50 MIC90 Range % susceptible (breakpoint)
a
Acinetobacter spp. (43)
BMS284756 >4 >4 0.03 to >4 34.9/39.5 (2/4)
Ciprofloxacin >2 >2 0.25 to >2 37.2 (1)
Gatifloxacin 4 >4 0.03 to >4 34.9 (2)
Gemifloxacin 4 >4 0.03 to >4 34.9 (0.25)
Levofloxacin 4 >4 0.03 to >4 34.9 (2)
Pseudomonas aeruginosa (129)
BMS284756 4 >4 0.12 to >4 50.4/60.5 (2/4)
Ciprofloxacin 0.25 >2 0.25 to >2 62.8 (1)
Gatifloxacin 1 >4 1 to >4 58.9 (2)
Gemifloxacin 0.5 >4 0.03 to >4 45.0 (0.25)
Levofloxacin 1 >4 0.06 to >4 62.0 (2)
Stenotrophomonas/Burkholderia group (97)
BMS284756 2 >4 0.12 to >4 60.8/83.5 (2/4)
Ciprofloxacin 2 >2 0.25 to >2 43.3 (1)
Gatifloxacin 1 2 0.06 to >4 91.8 (2)
Gemifloxacin 0.5 2 0.03 to >4 26.8 (0.25)
Levofloxacin 1 2 0.12 to >4 81.4 (2)
aInterpretive breakpoint criteria are those published by the NCCLS [15] or suggested in cited references [7].
Table 2 Comparison of BMS284756 E test MIC results with those obtained by reference broth microdilution methods [9]a
E test MIC/reference MIC
Organism (no. tested) 8 4 2 1 0.5 0.25 0.12
Acinetobacter (43) 0 0 5 4 0 0 0
Pseudomonas aeruginosa (129) 0 0 6 38 33 1 0
Stenotrophomonas/Burkholderia spp. (97) 0 0 4 31 29 12 5
Total (269) 0 0 15b 73b 62b 13 5
aOnly on-scale results for both tests were used to assess essential agreement (168 organism tests).
bEssential agreement 1 log2 dilution was 89.3% (97.0% 2 log2 dilution steps).
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Several additional, rarely isolated Gram-negative
species were tested against BMS284756 during this
investigation. The BMS284756 MIC results for
these nine strains were: Agrobacterium spp. (one
strain), 12 mg/L; Alcaligenes xylosoxidans (two
strains), >32 mg/L; Aeromonas sobria (one strain),
0.5 mg/L; Ochrobactrum anthropi (one strain),
1.5 mg/L; Pasteurella multocida (one strain),
0.006 mg/L; and Pseudomonas spp. NOS (three
strains), 0.25–1.5 mg/L.
D I S C U S S I O N
This investigation studied the potency of
BMS284756 tested against selected strains of
Acinetobacter spp., Pseudomonas aeruginosa and S.
maltophilia/Burkholderia spp. group, and further
assessed the inter-method susceptibility results
for the E test and disk diffusion method. The
results confirmed the four-to-eight-fold greater
potency of ciprofloxacin compared to BMS284756
reported by Fung-Tomc et al. [7] and Takahata et al.
[6] for Pseudomonas aeruginosa and Burkholderia
cepacia. For S. maltophilia and Acinetobacter spp.
strains, BMS284756 was generally as active, or
more potent than, ciprofloxacin [6,7], and levoflox-
acin shows some of these same advantages, having
current (1999) susceptibility rates of 78.2–88.6%
and 53.2–53.6% for S. maltophilia and Acinetobacter
baumannii, respectively [16].
When testing these species, accuracy has
become a concern, since the majority of these
infections occur in severely ill patients in the
hospital setting, regardless of patient age [17].
The E test appears to be an excellent and practical
alternative to the use of the reference broth micro-
dilution method for this quinolone, a finding
supported by similar success with this method
for gatifloxacin [8]. The disk diffusion method
also provided results that appear acceptable
for the manufacturer’s applied breakpoint for
BMS284756 susceptibility (4 mg/L) [7] or a lower
alternative (2 mg/L).
BMS284756, a novel desfluoroquinolone, has
demonstrated a wide spectrum of activity versus
Gram-positive and -negative aerobic pathogens, as
well as Bacteroides fragilis (MIC90, 0.5–0.78 mg/L)
[6,7]. More modest activity for BMS284756 has
been documented here, for non-fermentative
Gram-negative bacilli, with in vitro test accuracy
across several susceptibility methods and some
possible advantages against some species isolates
Figure 1 Scattergrams comparing the BMS284756 MIC
with the zone of inhibition around a 5-mg disk when
testing: (a) Pseudomonas aeruginosa (129 strains); (b)
Acinetobacter spp., 43 strains; and (c) Stenotrophomonas/
Burkholderia spp., 97 strains. Vertical broken lines indicate
preliminary zone diameter breakpoint criteria correlating
with the proposed 4 mg/L MIC indicating susceptibility
[7].
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compared to ciprofloxacin or levofloxacin. Con-
tinued in vivo investigations are encouraged to
clarify the optimal breakpoint to predict clinical
success.
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